👩⚕️ The Cell Shuttle is designed to meet global patient demand, reduce costs, and minimize process failure rates.
💉 This milestone ensures that Cellares is on track to have clinical readiness by the end of 2024.
🚀 Cellares co-founder and CEO, Fabian Gerlinghaus, stated that they have built the first Cell Shuttle that will be used to make drugs for humans.
🔬 The Cell Shuttle is an ultra-high-throughput, automated platform that can produce thousands of cell therapies annually.
🎯 Cellares has already inked eight commercial agreements and plans to build dozens of Cell Shuttles to support commercial-scale engagement.
💪 They aim to become the de facto standard for cell therapy manufacturing and meet the total patient demand for cell therapies globally.
🌐 Cellares will continue to expand its facilities, including a new one in Belgium, to be a global distributor of cell therapies.
Introduction:
Cellares, a biotechnology company, has announced the completion of its first clinically-ready Cell Shuttle, a cell therapy manufacturing platform. This milestone represents a significant step towards meeting global patient demand for cell therapies while reducing costs and process failure rates. The Cell Shuttle is designed to automate the cell therapy manufacturing process, making it more efficient and compliant with Current Good Manufacturing Practice (CGMP) standards.
- Cellares has completed the construction of its first clinically-ready Cell Shuttle, a platform for manufacturing cell therapies.
- The Cell Shuttle is designed to meet global patient demand and reduce costs and process failure rates.
- The platform is fully automated and CGMP-compliant, making it suitable for drug manufacturing for human use.
- Cellares plans to support clinical trials for various biotech and pharma companies in the coming years.
- The company aims to become the de facto standard for cell therapy manufacturing by offering unprecedented scale, capacity, and cost reduction.
Conclusion:
Cellares’ completion of the CGMP-compliant Cell Shuttle represents a major milestone in cell therapy manufacturing. The platform’s automation and capacity to support the production of clinically-ready cell therapies for human use have significant implications for the biotech and pharma industries. Cellares aims to become a global distributor of cell therapies by constructing additional Cell Shuttles and expanding its operations in Europe and Japan. The company’s innovative approach to cell therapy manufacturing has the potential to revolutionize the industry and improve patient access to these cutting-edge treatments.
